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TRAM-34The mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1 has recently been
discovered in the HCT116 colon tumor-derived cell line, which expresses relatively high levels of this protein
also in the plasma membrane. Electrophysiological recordings revealed that the channel can exhibit different
conductance states and kinetic modes, which we tentatively ascribe to post-translational modiﬁcations. To
verify whether the localization of this channel in mitochondria might be a peculiarity of these cells or a more
widespread feature we have checked for the presence of mtKCa3.1 in a few other cell lines using biochemical
and electrophysiological approaches. It turned out to be present at least in some of the cells investigated.
Functional assays explored the possibility that mtKCa3.1 might be involved in cell proliferation or play a role
similar to that of the Shaker-type KV1.3 channel in lymphocytes, which interacts with outer mitochondrial
membrane-inserted Bax thereby promoting apoptosis (Szabò, I. et al., Proc. Natl. Acad Sci. USA 105 (2008)
14861–14866). A speciﬁc KCa3.1 inhibitor however did not have any detectable effect on cell proliferation or
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Over the past ﬁfteen years or so the operational concept of
monovalent ion “leaks” through the inner mitochondrial membrane
(IMM) has been replaced by ﬁrm evidence for the presence of a multi-
component, regulated transport machinery for both cations and anions
[1–6]. K+ is themajor intracellular cation, and a relevant mitochondrial
K+ cycle consisting of electrophoretic, channel- and “leak”-mediated
inﬂux, andelectroneutral efﬂuxviaK+/H+exchange is inplace. TheK+-
selective pores reported to be present in the IMM so far are ﬁve, all of
them mitochondrial counterparts of channels known to be present in
the cellular membrane: mtKATP [3,7–9], whose presence in mitochon-
dria is still debated (for a recent discussion see [5]), Shaker-type KV1.3
[10–12], twin-pore TASK-3 [13], and two (out of the three known) types
of Ca2+-activated K+ channels: KCa1.1 (BKCa) and KCa3.1 (IKCa) [14–20].
The Ca2+-activated, high-conductance mtBKCa (KCa1.1) was ﬁrst
observed inmitoplasts froma glioma cell line [14], and it has been found
also in the IMMof cardiomyocytes [15] and in skeletalmuscle [16], liver
[17] and brain [18] mitochondria. Its activity has furthermore recently
been observed in bilayer experiments with IMM preparations from
potato mitochondria [19]. Recently, our group has characterised the
intermediate-conductance KCa3.1 in the IMM of HCT116 cells [20]. This
paper reports further progress in the study of this latter channel.
Fig. 1. KCa3.1 is not abundant in C-26mitochondria. A representative experiment showing
Western blots of the same preparations (1: cell lysate; 2: membrane-enriched fraction;
3: Percoll-puriﬁed mitochondria). The same amount of proteins (50 µg) was loaded in
each lane. The blots on each horizontal line were obtained from the same PAGE gel and
were blotted and developed together. The bands containing mitochondrial markers
(29 kDa Bak, 30 kDa prohibitin) are more intense in the Percoll-puriﬁed fraction, while
those corresponding to contamination markers (110 kDa SERCA, 140 kDa PMCA) and to
KCa3.1 (55 kDa) decrease. Similar results were obtained in 2 other experiments.
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signalling, it is not surprising that cells should have a variety of Ca2+-
activated K+ channels. Besides KCa1.1 (reviews: [21,22]) and KCa3.1
(rev.: [22–24]), these include the KCa2 family of three members, also
known as SKCa because of their lower conductance (rev.: [25]). Two
major functions of these channels are to link cytoplasmic Ca2+ levels
and PM potential – a negative feedbackmechanism in excitable cells –
and to provide a Ca2+-dependent K+ permeation pathway, important
in secretory epithelia.
KCa1.1 (also called Slo, Slo1, and BK ormaxi K channel due to its large
conductance of about 260 pS) forms tetrameric complexes composed of
four ion-conducting α subunits, each with 7 transmembrane segments
and an intracellular domain which acts as Ca2+ sensor, and four
regulatory β subunits (four variants of which exist). Besides Ca2+, it is
modulated by voltage and mechanical stress. It is expressed by a wide
variety of cells, including neurons and myocytes, and has pleiotropic
functions. It can respond to transient Ca2+ increases (“sparks”) originated
by opening of PM Ca2+ channels or sarcoplasmic reticulum ryanodine
receptors, and it has been observed to form clusters optimally positioned
for such local responses, for which it seems to have been particularly
designed by evolution since it responds to [Ca2+] in the µM range.
KCa2.1/2/3 (SK) differs in most respects, exhibiting low single-
channel conductances (2–10 pS), insensitivity to voltage, cooperative
activation by Ca2+ in the 0.3–0.7 µM range through tightly associated
calmodulin, and voltage-dependent block by intracellular cations
resulting in inward rectiﬁcation [26]. These channels are subject to
regulation by phosphorylation/dephosphorylation events [27], and
heterotetramers can form. They are expressed in the nervous system
(where they can regulate the ﬁring pattern of neurons) and in various
other organs, including heart, liver and muscle, and cell types – such as
endothelial cells and lymphocytes – where they often share their
functionswithKCa3.1. Like the othermembers of the family, they can co-
localize with speciﬁc Ca2+ sources in a cell type-speciﬁc manner.
KCa3.1 (SK4, Gardos channel, IK1, IKCa1, Kcnn4) is closely related to
KCa2 and is not as ubiquitous as KCa1.1, but it is nonethelesswidespread,
being present in, e.g., erythrocytes, lymphocytes, liver and pancreas, but
not in excitable cells. Thus, the presence of KCa3.1 in cardiomyocytes has
not been reported, although the channel is expressed by vascular
smooth muscle, endothelial and blood cells [22] and cardiac ﬁbroblasts
[28] and is therefore deﬁnitelypresent in theheart as awhole. It is highly
expressed in a variety of cancer cell lines, including prostate PC-3 [29],
breast MCF-7 [30] and glial GL-15 [31] lines, and it is thus considered a
possible target for anti-cancer intervention [24]. Like the other Ca2+-
dependent K+ channels, it functions in several physiological processes.
It has been shown, for example, that KCa2 and KCa3.1 are important for
agonist-evoked NO synthesis in vascular endothelial cells, vasorelaxa-
tion, and vascular smooth muscle cell (VSMC) proliferation and
migration (and thus in atherosclerosis) [32–34]. KCa3.1 plays a major
role in colonic salt secretion [35,36]. The channel has a non-ohmic
single-channel conductance of 10–90 pS, is voltage-insensitive and
responds to [Ca2+] in the sub-µM range, again due to a calmodulin
molecule tightly associated to each monomeric unit.
The functions of the mitochondrial K+ cycle have been identiﬁed
as the control of matrix volume and the regulation of ROS production
[2,3,37–39]. The former, a widely accepted notion, is in turn important
for the regulation of metabolic processes and the optimisation of
bioenergetic performance [40–42]. The latter, a more controversial
issue [4,6,43–48], is considered to impact on cell-wide signalling and
cell fate, and to explain the protection afforded by administration of K+
channel openers against I/R damage, thought to involve activation of
the RISK salvage pathway and downstream inhibition of the
mitochondrial permeability transition [49–52]. Enhanced ROS gener-
ation appears to depend on the development of an inward K+ current
across the mitochondrial membrane, since it is also induced by the
ionophore valinomycin [53,54] and by the viral protein p13, which
causes K+ inﬂux [55]. In fact, similar effects are reportedly producedbyactivation of eithermtKATP or mtBKCa, and Ca2+-sensitive K+ channels
may constitute one of the links between mitochondrial Ca2+ handling
and ROS generation [56].
Contrary to the cell protecting role assigned to mtKATP andmtBKCa,
mtKV1.3 promotes apoptosis [11]. As recapitulated in the paper by
Gulbins et al. 2010 [12], in lymphocytes the pro-apoptotic BH3-only
protein Bax, after incorporating into the OMM, interacts with the
vestibule of IMMKV1.3 channels, in amanner reminiscent of themode
of action of channel-blocking peptide toxins such as MgTx and ShK.
This leads, again, to the production of ROS which in this case favour
the detachment and release of cytochrome c. In principle, mtKCa3.1
may act either way: it is expected to open (before KCa1.1 because of its
higher afﬁnity for Ca2+) as matrix Ca2+ increases, thus perhaps
contributing to ROS production and eventually toMPTP inhibition, but
an interaction of its periplasmic domain with Bax imbedded in the
OMM was also a possibility, which we have veriﬁed.
2. Materials and methods
2.1. Materials, cells and mitochondria
Ionomycin and DC-EBIO (5,6-dichloro-1-ethyl-1,3-dihydro-2H-ben-
zimidazol-2-one)were fromTocris Cookson (Bristol, UK). Cyclosporin A
was fromLDLabs (Woburn,MA,USA), AnnexinV-Fluoswas fromRoche
(Milan), charybdotoxin was from Alomone Labs (Jerusalem, Israel). All
other reagents andmaterials were from Sigma (Milan) unless speciﬁed.
Cells were grown in Dulbecco's modiﬁed Eagle medium (DMEM)
plus 10 mM HEPES buffer, 10% (v/v) fetal calf serum (Invitrogen),
100 U/mL penicillin G, 0.1 mg/mL streptomycin, 2 mM glutamine
(GIBCO) and 1% nonessential amino acids (100× solution; GIBCO), in a
humidiﬁed atmosphere of 5% CO2 at 37 °C. mtDsRed-transfected HeLa
cells were obtained as already described for HCT116 cells [20].
Mitochondria for patch-clamp experiments were obtained by differen-
tial centrifugation [57]. For Western blotting a further puriﬁcation was
obtained by centrifugation (8500 g, 10 min, 4 °C) on a discontinuous
Percoll gradient composed of 60, 30 and 18% Percoll in TES buffer
(300 mM sucrose, 10 mM TES, 0.5 mM EGTA, pH 7.4). The ﬂoating
material was discarded, and the fraction at the lower interface collected
andwashed three times by centrifugation at17,000 g for 5 min. Theﬁnal
pellet was resuspended in TES buffer to form fraction 3 in Fig. 1.
Fig. 2.mtKCa3.1 in HeLamitochondria. A) Exemplary current records at the indicated voltages, in standard symmetrical 150 mMKCl medium. B) i–V plot.●: averaged single-channel
amplitude data (N=6 to 13) from the experiment in A), ﬁtted with an exponential. Error bars indicate standard deviations. □: analogous data from 5 separate experiments on
HCT116 mitoplasts, under the same conditions (error bars have been omitted for clarity).
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Samples, dissolved in sample buffer, allowed to stand for 15 min at
R.T. andboiled for 5 min,were subjected to SDS-PAGE in10% acrylamide
minigels and transferred to a polyvinyldiﬂuoride (Pall Corporation,
Pensacola, FLA, USA) sheet. Primary antibodies used were: anti-Bak NT
rabbit polyclonal (Upstate Biotechnology; cat. n. 06-536); anti-
prohibitin mouse monoclonal (Lab Vision MS-261-P); anti-SERCA-2
ATPasemousemonoclonal (Afﬁnity BioReagentsMA3-910); anti-PMCA
ATPase mouse monoclonal (Afﬁnity BioReagents MA3-914); polyclonal
anti-KCa3.1 (Alomone Labs APC-064) was raised in rabbit against aFig. 3.mtKCa3.1 exhibits distinct kinetic behaviours. Distributions of channel open (panels A
and D report data from two different experiments on HCT116 mitoplasts. Bin width: A: 1 m
experiments were conducted in symmetrical 150 mM KCl medium, at V=−60 mV.peptide comprising aa 350–363 of the rat channel. The immuno-
genic peptide was purchased from Alomone. Secondary antibodies
(Calbiochem) were horseradish peroxidase-conjugated and used with
chemiluminescence detection (Pierce) usingﬁlm or digital imaging by a
Bio-Rad ChemiDoc XRS apparatus.
2.3. Recombinant proteins
hBax(ΔC) (amino acids 1–170) and hBclxL were cloned into pGEX-
3X as GST fusion proteins, expressed in BL21A1 and puriﬁed from
bacterial lysates using glutathione-Sepharose [11,12].and C) and closed (B and D) times ﬁtted with a single exponential. Panels A and B and C
s; B: 20 ms; C and D: 5 ms. Insets in A) and C) show exemplary current records. The
Fig. 4. mtKCa3.1 can adopt a lower-conductance state. A continuous current record
showing the activity of a mtKCa3.1 channel in an HCT116 mitoplast. The red and green
horizontal lines highlight the difference in current amplitude, the purple line indicates
the background current level. See text for details.
1263N. Sassi et al. / Biochimica et Biophysica Acta 1797 (2010) 1260–12672.4. Vitality and apoptosis assays
For cell growth/viability tetrazolium reduction (MTT) assays,
HCT116 cells were seeded in standard 96-well plates and allowed to
grow in DMEM (200 µL) for 24 h. The growth medium was then
replaced with medium that contained the desired compounds (from
stock solutions in DMSO). The DMSO ﬁnal concentration was≤0.5% in
all cases. Four wells were used for each condition. The solution was
substituted by a fresh aliquot twice, at intervals of 24 h. At the end of
the third 24 h period, the medium was removed, cells were washed
with PBS, and 100 µL of PBS containing 10% CellTiter 96® AQUEOUS One
solution (Promega) were added into each well. After 1 h of colour
development at 37 °C, absorbance at 490 nm was measured using a
Packard Spectra Count 96-well plate reader.
For the evaluation of apoptosis we plated HCT116 cells (300,000
cells/well) in a 6-well plate. After attachment overnight, cells were
treated for 2, 6 and 12 h with the desired drugs (in the example of
Fig. 6B: Tram 1 µM, Verapamil 30 µM (as inhibitor of MDR pumps),
arachidonic acid 250 µM, as indicated) in DMEM or HBSS. After
treatment, cells were harvested, washed with PBS, resuspended in
FACS Buffer (Hepes 10 mM; NaCl 135 mM, CaCl2 5 mM, pH 7.4) and
incubated with propidium iodide and Annexin V-Fluos in the dark at
37 °C for 15 min. Samples were then immediately analyzed by using a
Beckton Dickinson FACScan ﬂow cytometer (BD Biosciences). Data
were processed using CellQuest® (BD Biosciences) and WinMDI2.8
(freeware; http://facs.scripps.edu/software.html, by Joe Trotter, the
Scripps Institute) software. For DNA fragmentation assays, after
washing the cells were resuspended in PBS, an equal volume of 70%
ethanol was slowly added under continuous stirring, and the
suspension was incubated overnight at 4 °C or for 30 min at R.T.
After this permeabilization step, duringwhich fragmented DNA is lost,
the cells were washed in PBS, resuspended in PBS with RNAse A
(20 µg/mL, 1400 units/mL) and incubated for 30 min at R.T. 5 µg/mL
of propidium iodide were then added and the incubation continued
for 20 min on ice in the dark, after which the samples were analyzed
as above. Propidium ﬂuorescence intensity is proportional to the
amount of (unfragmented) DNA present.
2.5. Electrophysiology
Patch-clampexperiments on swollenmitochondria (mitoplasts) and
perforated-patch whole-cell experiments were conducted as described
in [20]. Axon pClamp software was used for voltage control and data
analysis. For experiments with mitoplasts the voltages reported are
those corresponding to the mitochondrial matrix. Inward currents are
considered negative and plotted downwards. In the perforated-patch
experiments illustrated in Fig. 5 all agents were bath-applied with a
superfusion system (Rapid Solution Changer RSC-200; BioLogic Science
Instruments, Claix, France). The time for solution exchange was about
500 ms; the solutionwas perfused via a glass pipette positioned at 300–
500 μmfromthecell. ThemaximalDMSOconcentration in the recording
solution was always less than 1%.
3. Results
A point of obvious relevance for an understanding of the physiologi-
cal role of mtKCa3.1 is whether its localization in mitochondria is a
peculiarity of the HCT116 cell line (human colorectal carcinoma), in
which it was discovered, or is instead a common occurrence in cells
expressing the channel. We therefore veriﬁedwhether we could obtain
evidence of its presence in mitochondria isolated from a few cell lines.
Somewhat to our surprise, we could not reliably detect mtKCa3.1 in
either of two colorectal adenocarcinoma cell lines: Caco-2, a human line
(not shown), or C-26, a murine one (Fig. 1). In both cases the channel is
present at the cell level, but in Western blots on progressively purer
mitochondrial fractions the intensity of its band decreases as those ofPM and ER markers likewise decrease and those of mitochondrial
markers increase. Such a trend does not completely rule out the
presence of the protein in mitochondria, but it does indicate that, if
present at all, it has a low abundance.
mtKCa3.1 turned out instead to be present in HeLa, of human cervix
adenocarcinoma origin (Fig. 2), and in mouse embryonic ﬁbroblasts,
non-cancerous cells (not shown). KCa3.1 is known to be expressed
both by HeLa [58] and by ﬁbroblasts [59]. In the experiment of Fig. 2,
the recordings were obtained from a red-ﬂuorescing mitoplast,
isolated from HeLa cells expressing the mitochondria-targeted
mtDsRed [20]. The data plotting the averaged single-channel current
amplitudes vs. voltage (panel B, full circles) are shown to fall on the
same curve as analogous data obtained from HCT116 mitochondria
(squares), indicating that the same channel is involved. Our attempts
to establish the presence of mtKCa3.1 in rat heart mitochondria have
failed so far to provide a reliable answer.
Observation of the activity of mtKCa3.1 at the single-channel level
allowed us to identify previously undescribed electrophysiological
characteristics. The channel exhibits at least two well-deﬁned rapid
kinetic modes: a more frequently encountered one with a short mean
open dwell time (time constant (τ)∼2 ms), a longer closed dwell time
(τ∼40 ms) and a correspondingly low (voltage-independent) open
probability (Fig. 3A and B), and one with longer-lasting (τ∼17 ms)
openings and shorter closures (τ∼12 ms) (Fig. 3C and D). “Bursting”
behaviour, conductance and voltage dependence of the unitary conduc-
tance and of the open probability were similar for the two forms;
channels operating in either mode appeared to be equally sensitive to
inhibition by TRAM-34 or clotrimazole, two speciﬁc inhibitors of
intermediate-conductance Ca2+-activated K+ channels (not shown).
Rarely, the channel also operated in a lower-than-usual conductance
state. In the example shown in Fig. 4, a channel with a chord
conductance of about 22 pS at−70 mV gave way to the usual activity
with a chord conductance of about 36 pS. Since the two types of activity
were never observed together, and a subsequent addition of clotrima-
zole abolished all activity (not shown), we attribute both conductances
to one mtKCa3.1 channel.
mtKV1.3 interacts with the pro-apoptotic protein Bax, as shown,
amongother evidence, by patch-clampexperiments inwhichwhole-cell
current conducted by PM KV1.3 was inhibited by externally applied
recombinantGST-Bax(ΔC) [11].We therefore checkedwhether a similar
interactionmight take place between KCa3.1 in the plasmamembrane of
HCT116 cells and this pro-apoptotic protein. Stable macroscopic KCa
currents, recorded in the perforated-patch mode, were activated by
applying the Ca2+ ionophore ionomycin (0.5 µM) plus the small/
intermediate KCa channel openerDC-EBIO (100 µM). Time courses of the
current in response to the various agents were built by plotting the
outward current assessed at 0 mV from voltage ramps from −100 to
100 mV (Vholding=0mV), applied every 5 s (Fig. 5). After stabilization of
the current, GST-Bax(ΔC) was applied at 8.25 or 13.2 nM. This had no
effect on the amplitude of the ionomycin+DC-EBIO-elicited current,
whichwas instead fully blocked by theKCa3.1 channel antagonist TRAM-
34 (3 μM) (N=3). This observation indicates that there is no KCa3.1
block by GST-Bax(ΔC) at any voltage, and no modiﬁcation of the
permeation properties of the channel. Using the same experimental
protocol, we also veriﬁed the effects of GST-BclxL (30 nM) on the KCa3.1
currents. GST-BclxL was, as expected, similarly ineffective (not shown).
Fig. 5. Bax has no effect on KCa3.1 currents in HCT116 cells. A) Time course of the iono+DC-EBIO-activated KCa3.1 current from a HCT116 cell in whole-cell perforated conﬁguration.
Each data point represents the KCa3.1 current assessed at 0 mV from voltage ramp pulses delivered every 5 s under varying experimental conditions: i) control, ii) ionomycin+DC-
EBIO (500 nM+100 µM) alone, iii) iono+DC-EBIO (500 nM+100 µM) plus GST-Bax(ΔC) (8.25 nM), and iv) ionomycin+DC-EBIO (500 nM+100 µM) plus TRAM-34 (3 μM).
B) Representative current traces in response to voltage ramps from−100 to+100 mV (1 s duration, Vholding: 0 mV), under the various pharmacological conditions shown in panel A.
Numbers indicate the corresponding sweep in the time course display in panel A.
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membrane-permeable inhibitor TRAM-34, by itself or in combination
with inhibitors of MDR efﬂux pumps (Cyclosporin A, Probenecid,
Verapamil, and Tamoxifen), had any effect on cell vitality or could
induce apoptosis or enhance apoptosis induction by staurosporin.
Assessment was carried out using cell counting, the MTT assay (N=3),
Annexin/propidium staining (N=8) and DNA fragmentation assays
(N=3) (see Materials and methods for details), using staurosporin,
indometacin and arachidonic acid as control apoptosis inducers. We
could not detect an effect on either cell growth or cell death. Fig. 6 shows
two representative experiments. The same result was obtained using
the impermeable and less selective blocker charybdotoxin (not shown).
4. Discussion
The data presented above prove that the presence of the
intermediate-conductance Ca2+-activated K+ channel is not a
peculiarity of HCT116 cells (nor of cancerous cells, since it is present
in the mitochondria of MEF). The mitochondrial subpopulation of
KCa3.1 seems to be regulated case by case. Thus, in cell lines of colonic
origin it may be detectable (HCT116) or undetectable (Caco-2, C-26).
This in turn suggests (although it does not prove) that this population
does not originate from an insufﬁciently selective targeting, i.e., KCa3.1
does not appear in mitochondria “by mistake”, but presumably as a
consequence of physiological events peculiar to each cell type. Other
cases of cell type-speciﬁc localization of a protein in mitochondria as
well as in another cellular compartment have been identiﬁed. ForFig. 6. TRAM-34 has no effect on HCT116 cell proliferation and does not induce cell death. A)
assayed after three days of growth (see Materials and methods for details). Conditions: 1:
4: TRAM-34, 2 µM, Cyclosporin A, 2 µM, and Probenecid, 100 µM; 5: Cyclosporin A, 2 µM, and
Cells were incubated in DMEM in the presence of the speciﬁed substances for 6 h, then treexample, COX-2 is present in the mitochondria of several cancer cell
lines, but not in those of ﬁbroblasts or endothelial cells, whereas
calcium-independent phospholipase A2 was found in the mitochon-
dria of ﬁbroblasts as well as in some cancerous cell lines [60].
One way a regulation of KCa3.1 localization might take place is via
modulationofmembrane/protein trafﬁc, a signalling-controlledprocess
(e.g.: [61,62]). One possibility is caveolae/lipid rafts-mediated trafﬁc. A
trafﬁc route between caveolae, the endosomal system, the ER and Golgi
has been identiﬁed [63–66], and a functional interaction of caveolae
with mitochondria as well is suggested by proteomics proﬁling of the
caveolae [67,68]. Caveolin-1 is targeted to various cellular compart-
ments, including mitochondria, depending on cell type [69]. Garlid and
coworkers have proposed that vesicular signalosomes originating from
caveolae migrate to mitochondria, bind to OMM receptors and activate
mtKATP via phosphorylations [70,71]. An interaction of the endosomal
endocytosis pathway with mitochondria is also suggested by some
observations [72]. Delivery of membrane proteins to mitochondria may
also conceivably take place at ER-mitochondrion contact sites. These
involve a differentiated ER membrane, MAM [73,74], are mediated by
proteins such as PACS [75,76] andmitofusin 2 [77] and are sites of inter-
membrane transfer of phospholipids [78]. Regulation at themembrane-
trafﬁc level might result in the protein being present in mitochondria at
different levels depending on cellular factors. Hypothetically, this might
also explain the contradictory results in the literature on the presence or
lack of KATP and KCa1.1 mitochondrial subpopulations.
IMM channels are furthermore subject to regulation at the molecu-
lar level. In the case of mtKATP, evidence has been presented for anRepresentative results of a tetrazolium salt (MTT) reduction assay. Cells were sowed and
control (no addition); 2: TRAM-34, 2 µM; 3: TRAM-34, 2 µM, and Cyclosporin A, 2 µM;
Probenecid, 100 µM. B) A representative apoptosis assay using ﬂow cytometry (FACS).
ated with propidium and Annexin as described in Materials and methods.
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activation can cause caveolin-1- and cholesterol-dependent internali-
zation of PMKATP channels in vascular smoothmuscle cells [80]. PKGhas
also been proposed to be involved in signalling targeting mtKATP [81].
mtKCa1.1 is regulated by PKA [82–84]. Whether analogous processes
impact on mtKCa3.1 is unknown, but it seems plausible to associate
different kinetic and conductance properties (Figs. 3 and 4) with
differences in post-translational modiﬁcations.
Roles have been assigned to KCa3.1 in a variety of cellular processes
(see the Introduction and [20]), but its function can apparently be
largely taken over by its smaller- and larger-conductance relatives, so
that knock-out animals exhibit relatively mild phenotypes [85,86]. At
the cell-culture level we also found it hard to identify clear short-term
consequences of its inhibition at the plasma membrane (with
charybdotoxin, not shown) or throughout the cell (with TRAM-34)
(Fig. 6). In principle mtKCa3.1 ought to be able to mimic, at least to an
extent, mtKCa1.1 functions, with the possibly relevant difference of
activating at lower matrix Ca2+ levels (sub-µM vs. µM range). It is
interesting in this context that the two channels have been recently
found to interact, with KCa3.1 inhibiting KCa1.1 [87,88]. We had
hypothesized [20] that mtKCa3.1 might act similarly to mtKV1.3 [11]
and interact with Bax. Experimental veriﬁcation however has failed to
support this hypothesis (Fig. 5). It seems therefore that the interaction of
Bax with K+ channels does not require simply a set of negative charges
in the channel vestibule, but depends on more speciﬁc features. On the
basis of computational simulations and of previousmutagenesis studies
[89], Yu et al. [90] have identiﬁed 5 channel residues, Tyr-400, Asp-402,
His-404, Asp-386 and Gly-380, as being of major relevance for KV1.3-
toxin interactions. His-404 is absent in KCa3.1 (Gly-380 corresponds to
an Ala residue in KCa3.1). His-404 accounts for the pH-dependence of
the interaction between the channel and some toxins, as well as with
Bax [12]. Aspartates at positions 375 and 376 in the turret region of
Kv1.3 do not have an equivalent in KCa3.1 [89], so that the formal
negative charge in this region, presumably important for the interaction
with Bax Lys128, is 1/monomer in KCa3.1 vs. 3 in KV1.3.
In summary, the roles of mtKCa3.1 in mitochondrial and cellular
physiology may be at least in part redundant, in analogy to what
seems to be the case at the cellular level, since fully functional
mitochondria exist without it (in cells not expressing the channel but
apparently also in cells which do express it). The possibility remains
that the channel may play a major role in some speciﬁc, yet to be
discovered, process, but the data presented here do not support a key
role in the control of cell proliferation or drug-induced apoptosis.
Where present, mtKCa3.1 is fully expected to contribute to the IMMK+
conductance following an increase in matrix [Ca2+]; the relevance of
this contribution in comparison with other K+ permeation pathways
remains to be explored. Themechanisms accounting for its presence in
mitochondria need to be investigated, and may well apply to other
proteins with multiple localisations.Acknowledgements
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